GlassScriptPhysician profile
Duke H Nguyen
NPI 1679557797
$108,975.48
in general payments reported to CMS, 2019-2025
10 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $6,228 · 2021: $9,567 · 2022: $15K · 2023: $18K · 2024: $20K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Travel and Lodging: $5,739 · Consulting Fee: $4,620 · Food and Beverage: $3,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,250.00 |
| Travel and Lodging | $5,738.58 |
| Consulting Fee | $4,620.00 |
| Food and Beverage | $3,402.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $92,615.69 | 2019-2025 | Vemlidy, Livdelzi |
| Phathom Pharmaceuticals, INC. | $13,391.54 | 2024-2025 | Voquezna |
| Medtronic, INC. | $2,210.79 | 2024-2025 | Gi Genius |
| Madrigal Pharmaceuticals | $144.17 | 2024 | Rezdiffra |
| Abbvie INC. | $138.23 | 2024-2025 | |
| Redhill Biopharma INC. | $133.00 | 2021 | |
| Celltrion USA INC. | $129.00 | 2025 | Zymfentra, Vegzelma |
| Novo Nordisk INC | $120.90 | 2021 | |
| Braintree Laboratories, INC. | $71.52 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.64 | 2025 | Eohilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duke Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.